Recombinant Cynomolgus Lymphotoxin beta R/TNFRSF3 Fc, CF
Recombinant Cynomolgus Lymphotoxin beta R/TNFRSF3 Fc, CF Summary
Product Specifications
Cynomolgus Monkey Lymphotoxin beta R/TNFRSF3 (Ser28-Met227) Accession # XP_005569951.1 | IEGRMD | Human IgG1 (Pro100-Lys330) |
N-terminus | C-terminus | |
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
10759-LR
Formulation | Lyophilized from a 0.2 μm filtered solution in PBS. |
Reconstitution | Reconstitute at 500 μg/mL in PBS. |
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Scientific Data
Recombinant Cynomolgus Lymphotoxin beta R/TNFRSF3 Fc Chimera (Catalog # 10759-LR) inhibits Lymphotoxin alpha1/beta2-induced IL-8 secretion in A375 human melanoma cells. The ED50 for this effect is 30.0-180 ng/mL in the presence of 100 ng/mL Recombinant Human Lymphotoxin alpha1/beta2 (8884-LY).
2 μg/lane of Recombinant Cynomolgus Monkey Lymphotoxin beta R/TNFRSF3 Fc Chimera (Catalog # 10759-LR) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 57-68 kDa and 114-136 kDa, respectively.
Reconstitution Calculator
Background: Lymphotoxin beta R/TNFRSF3
Lymphotoxin beta receptor (LT beta R), previously called TNF RIII or TNF R‑related protein (TNF Rrp), is a type I transmembrane glycoprotein within the TNF receptor superfamily, designated TNFRSF3 (1‑3). Cynomolgus monkey and rhesus macaque LT beta R cDNA encodes 435 amino acids (aa) including a 30 aa signal peptide, a 197 aa extracellular domain (ECD), a 21 aa transmembrane domain, and a 187 aa cytoplasmic domain. The ECD contains four cysteine‑rich motifs characteristic of the TNF receptor superfamily (1, 2). Within the ECD cynomolgus monkey LTBR shares 65‑75% aa sequence identity with human, mouse, rat, canine, porcine, equine and bovine LT beta R. Soluble LT beta R can be formed by proteolytic cleavage of the ECD, and is an inhibitor of transmembrane LT beta R, as is recombinant LT beta R, which inhibits autoimmunity (3‑6). LT beta R is expressed by visceral, lymphoid, and other stroma, epithelia and myeloid cells, but not lymphocytes (2, 4). LT beta R ligands include homotrimers of LIGHT (TNFSF14; also a ligand for HVEM) and the heterotrimeric lymphotoxin LT alpha 1/ beta 2 (3, 4, 6). Depending on the cell type and expression of TRAF3, activation of LT beta R has been shown to induce canonical (IKK/RelA; pro‑inflammatory) or alternative (NIK/RelB; lymphoid organogenic) NF kappa B activation (6, 7). LT beta R is expressed on mesenchymal stromal organizing cells that give rise to stroma of primary (thymus), secondary (tonsils, lymph nodes and Peyers patches) and tertiary (ectopic inflammatory) lymphoid structures (3‑5, 8‑10). Secondary immune tissues are absent in LT beta R‑deficient mice (3-5). LT beta R engagement induces production of IL‑7, RANK, TRANCE/RANK L, VEGF‑C, adhesion molecules such as VCAM‑1, ICAM‑1 and MAdCAM, and chemokines such as CXCL13, CCL19 and CCL21 (3, 8 ‑ 10). LT beta R is expressed by hepatocytes, is up‑regulated in regeneration, hepatitis and hepatocellular carcinoma, and influences lipid metabolism and atherosclerosis (4, 6, 11). It regulates cell growth and can initiate inflammation‑related carcinogenesis (6, 11).
- Crowe, P.D. et al. (1994) Science 264:707.
- Force, W.R. et al. (1995) J. Immunol. 155:5280.
- McCarthy, D.D. (2006) Immunol. Res. 35:41.
- Tumanov, A.V. et al. (2007) Curr. Mol. Med. 7:567.
- Boehm, T. et al. (2003) J. Exp. Med. 198:757.
- Wolf, M.J. et al. (2010) Oncogene 29:5006.
- Bista, P. et al. (2010) J. Biol. Chem. 285:12971.
- van de Pavert, S.A. et al. (2010) Nat. Rev. Immunol. 10:664.
- Mouri, Y. et al. (2011) J. Immunol. 186:5047.
- Vondenhoff, M.F. et al. (2009) J. Immunol. 182:5439.
- Haybaeck, J. et al. (2009) Cancer Cell 16:295.
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Cynomolgus Lymphotoxin beta R/TNFRSF3 Fc, CF
There are currently no reviews for this product. Be the first to review Recombinant Cynomolgus Lymphotoxin beta R/TNFRSF3 Fc, CF and earn rewards!
Have you used Recombinant Cynomolgus Lymphotoxin beta R/TNFRSF3 Fc, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image